Exclusive: A Judge is About to Rule on Pfizergate Case to Hold Big Pharma Accountable for Covid Vaccine Fraud

0


The last shred of hope for holding Big Pharma accountable for fraud now rests on a lawsuit against vaccine manufacturer Pfizer. In an update provided to Becker News, a judge is soon expected to issue his ruling on whether or not the ‘Pfizergate’ fraud case proceeds to trial.

“The judge is deciding, as I type, whether we go to discovery or the case is dismissed,” Pfizer whistleblower Brook Jackson tells Becker News.

After the CDC this week voted to add the Covid shots to its Childhood Vaccines Schedule, under the PREP Act, it has effectively been granted legal immunity to lawsuits. There is no legal immunity if Pfizer committed fraud, however.

In September, Pfizer whistleblower Brook Jackson came forward with her explosive report about the company’s alleged malfeasance, citing ‘falsified data’ and manipulated clinical trials.  In January, she filed a lawsuit against Pfizer for committing fraud against the American people,  In February, the judge ruled that the lawsuit, being led by attorney Robert Barnes, can proceed to pre-trial discovery phase. It is now on the verge of potentially going to trial.

Brook Jackson is a former clinical trial auditor who was fired after raising her concerns. She first came forward with inside information and documented evidence about Pfizer’s operations in a BMJ investigation conducted by Paul Thacker. The report raises serious red flags that the FDA and Pfizer engaged in massive fraud to justify vaccine mandates.

*” indicates required fields

“A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial,” the BMJ reported. “Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson (video 1), emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails.”

“Jackson has told The BMJ that, during the two weeks she was employed at Ventavia in September 2020, she repeatedly informed her superiors of poor laboratory management, patient safety concerns, and data integrity issues,” the report added. “Jackson was a trained clinical trial auditor who previously held a director of operations position and came to Ventavia with more than 15 years’ experience in clinical research coordination and management.”

The U.S. government has moved to dismiss the case, which cites the False Claims Act.

“The United States remains a real party in interest in this suit under the False Claims Act, even though it has not intervened in the case.,” the motion states. “The False Claims Act is the primary statute on which the Federal Government relies to combat fraud against the public fisc and to recover taxpayer dollars lost to fraud or false claims. The Government therefore has a substantial interest in the development of the law in this area and in the correct application of that law in this and similar cases. While fraud on the Food and Drug Administration or the failure to comply with clinical trial protocols could potentially give rise to False Claims Act liability in an appropriate case, in the instant case the complaint does not plead a sufficient nexus between the alleged clinical trial violations and the alleged requests for payment from the Government to support such liability.”

As related by one legal analyst, “Pfizer’s core argument in its Motion to Dismiss, which the US Government has now endorsed in its Oct. 4 statement of interest, is that clinical trials and clinical data from all of the sites, including the serious adverse event reports from the very start of the trials in Summer 2020, were not “material” or “necessary” to the FDA’s decisions to grant Emergency Use Authorization (Dec. 11, 2020) and approval (Aug. 23, 2021) to Pfizer’s product.”

In the latest court ruling on October 14, Brook Jackson’s Motion for Leave to Respond to Statement of Interest was granted and given until October 27, 2022 to respond. Robert Barnes, who is representing Jackson, discussed the Pfizergate case with attorney Viva Frei in February.

Digital strategist Kate for Truth lays out why Pfizer is terrified that the case will proceed to trial.

Due to the federal judge’s order, however, there is at least some hope for transparency and for accountability for Big Pharma and the public health bureaucrats who perpetrated this massive fraud on the American people. Support Brook Jackson’s case by donating to her legal defense.

Correction: Jackson first came forward with her allegations in September, not November as previously reported. The story has been updated to reflect that fact.



OPINION:
This article contains commentary which reflects the author’s opinion.




Source
Las Vegas News Magazine

Leave A Reply

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More